Navigation Links
Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
Date:2/24/2009

Produces 98% pure protein

THOUSAND OAKS, Calif., Feb. 24 /PRNewswire/ -- Bone Biologics, Inc. announced today that it's contract research and development organization, Aragen Bioscience, has completed development of a recombinant cell line and initial production process for UCB-1 (NELL-1) recombinant protein.

Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the founding scientists at UCLA. The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort. This platform technology is combined with DBX(R) demineralized bone matrix to promote bone growth in spinal fusion.

Aragen has produced UCB-1 (NELL-1) at a purity level Bone Biologics believes is sufficient for IDE submission. Results in animal trials using that protein have exhibited rapid bone growth, high quality of bone, and no ectopic bone growth. Efforts will now focus on scaling that process up to produce clinical grade product.

The platform technology will be subject to the FDA review and approval process, including clinical trials. It is not currently approved for use in humans.

Rick Srigley, CEO of Aragen Bioscience said, "This project has been exciting for us. UCB-1 (NELL-1) is a complex and challenging protein, but we believe that the cell line and process we have developed for Bone Biologics can be scaled up to provide protein at purity and productivity levels sufficient for Phase I clinical studies." William Jay Treat, Ph.D., President of Southwest BioProcessing Associates LLC, who has extensive experience in cell line development, scale-up optimization and commercial manufacturing provided key guidance during this process to Bone Biologics, said, "The professionalism, expertise, and awareness of keeping to a timeline by Aragen
'/>"/>

SOURCE Bone Biologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
2. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
3. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
4. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
5. Savient Submits Biologics License Application (BLA) for pegloticase
6. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
7. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
8. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
9. NuVasive Completes Acquisition of Osteocel Biologics Business
10. Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets
11. Pinnacle Biologics Announces Opening of Executive Offices in Bannockburn, Illinois and the Addition of Sandra Miller to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... NY (PRWEB) May 17, 2013 ... Topical BioMedics, Inc., has been listed among nationally ... in an initiative conducted by "U.S. News" Health ... has earned the “No. 1 Pharmacists Recommended ... 17 other national OTC brands, and is the ...
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... 17, 2013 The new Public-Private Partnership ... at the association’s recent annual meeting drew praise from ... Neelie Kroes, who called the action “a huge step ... stimulant to European innovation.” , The Board of Stakeholders ... new Photonics PPP at its 29 April meeting in ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... the accelerated development of new, safe and effective ... US and around the world, will become greater ... State University and Quintiles ( www.quintiles.com ), a ... leader in managing clinical research. The ...
... potential to save tens of thousands of lives each ... at the University of Massachusetts and the Serum Institute ... results from a Phase 1 study. The recently completed ... in protective antibody levels in the serum of treated ...
... ultrafine coal slurry has been successfully tested at the ... technology offers the possibility of reducing the coal slurry ... this new technology was presented Sept. 15 at the ... Cleaning coal after it has been mined is done ...
Cached Biology Technology:Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement 2New treatment for rabies advances after successful phase 1 trial in India 2New treatment for rabies advances after successful phase 1 trial in India 3Commercial-scale test of new technology to recover coal from sludge successful 2Commercial-scale test of new technology to recover coal from sludge successful 3
(Date:5/16/2013)... a commitment to the support of underrepresented minority ... Foundation has announced the inaugural AGA Investing in ... by the National Institute of Diabetes and Digestive ... underrepresented minority students to further their research careers ... establishing this new award, AGA demonstrates its commitment ...
(Date:5/16/2013)... used ancient shorelines to predict the stability of today,s largest ... shoreline from three million years ago, for example when ... to be evidence of a high sea level due to ... many scientists to think that if the world,s largest ice ... the same in our modern, progressively warming world. , ...
(Date:5/16/2013)... May 16, 2013 The relationship between the ... has not been clear. Schizophrenia is commonly associated ... There are clues that reduced IQ may be ... example, reduced cognitive ability may precede the onset ... present in healthy relatives of people diagnosed with ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2World's biggest ice sheets likely more stable than previously believed 2Genetic risk for schizophrenia is connected to reduced IQ 2
... reporting the first use of ordinary cotton thread and ... device microscopic technology that can transport fluids for ... chips shrink room-sized diagnostic testing equipment down to the ... in medicine, environmental sensing, and other areas. Their study ...
... the ethical dilemma involved in using human embryonic stem ... In particular, they are looking for drug-like chemical compounds ... cells now obtained from human embryos. That,s the topic ... (C&EN), ACS, weekly newsmagazine. C&EN Associate Editor Sarah ...
... including international researchers with a scientist from Cardiff University, ... panda,s unusual biological traits, including its famously restricted diet. ... genome for the first time and now, the genetic ... for the endangered species. Giant pandas are ...
Cached Biology News:Giant panda genome reveals new insights into the bear's bamboo diet 2
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: